Search This Blog

Tuesday, August 27, 2024

Lifecore Biomed projects flat F25 revenue

 Fiscal 2025 Outlook

The Company is providing guidance on a consolidated basis for full year fiscal 2025.

  • Revenue: Expected to be in the range of $126.5 million to $130 million
  • Adjusted EBITDA: Expected to be in the range of $19 million to $21 million. As noted above, the Company has changed its presentation of adjusted EBITDA to exclude stock-based compensation expense, which is anticipated to be in the range of $9.0 million to $10.0 million during fiscal 2025.
  • Capital expenditures: Expected to be in the range of $10 million to $14 million, excluding capitalized interest.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.